• In late April 2026, Abbott received FDA clearance for its next-generation Ultreon 3.0 AI-powered OCT imaging software, while also expanding its board to thirteen directors and adding Kevin Conroy and Paola Gonzalez following its Annual Meeting of Shareholders.
• Abbott simultaneously advanced its cardiovascular technology pipeline with new late-breaking trial data on pulsed field ablation and conduction system pacing devices, and registered a US$14.13 billion employee share offering shelf to support long-term capital and ownership plans.
• We’ll now examine how Abbott’s Ultreon 3.0 AI imaging approval and cardiac data updates influence the company’s existing investment narrative.

The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 17 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.

Abbott Laboratories Investment Narrative Recap

To be an Abbott shareholder, you generally need to believe in its diversified healthcare model, ongoing device innovation and capacity to defend margins despite recent earnings pressure and share price underperformance. The Ultreon 3.0 clearance and new cardiac data mostly reinforce Abbott’s cardiovascular technology pipeline, but do not materially change the near term focus on stabilising diagnostics and managing FX and tariff headwinds as key catalysts and risks.

Among the recent developments, the Ultreon 3.0 AI OCT approval stands out as most relevant here, because it directly expands Abbott’s interventional cardiology toolkit alongside its pulsed field ablation and conduction system pacing data. Together, these updates support the company’s existing narrative around device-led growth, while investors still need to watch how competitive and pricing pressures in diagnostics and diabetes care evolve against this innovation backdrop.

Yet while product approvals grab headlines, the pressure on diagnostic pricing and margins is something investors should be aware of if...

Abbott Laboratories’ narrative projects $59.7 billion revenue and $9.5 billion earnings by 2029. This requires 9.8% yearly revenue growth and a $3.2 billion earnings increase from $6.3 billion today.

Uncover how Abbott Laboratories' forecasts yield a $118.64 fair value, a 36% upside to its current price.

Exploring Other Perspectives

Five Simply Wall St Community fair value estimates cluster between US$118.64 and US$135.30, showing how differently people can view Abbott’s worth. Against that backdrop, the Ultreon 3.0 approval and new cardiac data sit alongside ongoing concerns about diagnostic pricing pressure, inviting you to weigh several competing views on the company’s future performance.

Explore 5 other fair value estimates on Abbott Laboratories - why the stock might be worth as much as 55% more than the current price!

The Verdict Is Yours

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Abbott Laboratories research is our analysis highlighting 4 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Abbott Laboratories research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Abbott Laboratories' overall financial health at a glance.

Want Some Alternatives?

These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

• Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 33 best rare earth metal stocks of the very few that mine this essential strategic resource.
• Invest in the nuclear renaissance through our list of 90 elite nuclear energy infrastructure plays powering the global AI revolution.
• We've uncovered the 12 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.